1. Home
  2. RGEN vs IBRX Comparison

RGEN vs IBRX Comparison

Compare RGEN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

N/A

Current Price

$177.23

Market Cap

10.0B

Sector

Health Care

ML Signal

N/A

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$9.18

Market Cap

8.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGEN
IBRX
Founded
1981
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0B
8.2B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
RGEN
IBRX
Price
$177.23
$9.18
Analyst Decision
Buy
Strong Buy
Analyst Count
22
4
Target Price
★ $189.70
$12.75
AVG Volume (30 Days)
880.1K
★ 8.8M
Earning Date
10-27-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 286.96
38.71
EPS
★ 0.24
N/A
Revenue
★ $141,236,000.00
$113,288,000.00
Revenue This Year
$12.04
$99.26
Revenue Next Year
$17.80
$95.57
P/E Ratio
$805.46
★ N/A
Revenue Growth
35.10
★ 668.31
52 Week Low
$100.99
$1.95
52 Week High
$198.87
$12.43

Technical Indicators

Market Signals
Indicator
RGEN
IBRX
Relative Strength Index (RSI) 63.35 64.16
Support Level $159.22 $6.68
Resistance Level N/A $9.54
Average True Range (ATR) 6.58 0.51
MACD 0.98 0.06
Stochastic Oscillator 75.63 90.41

Price Performance

Historical Comparison
RGEN
IBRX

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: